Evidence map›Paper›PMID 19343034›Full record

ReviewNature reviews. Cancer2009

Tumour necrosis factor and cancer.

Frances Balkwill

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05867004 (Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma), which is not on this map. Cited by 996 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
996citing papers in PubMed, 4 pooled it
34.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05867004 recruitingnot on this mapstarted 2023, after this paper: background citation

Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma

TypeobservationalSponsorInstitut Claudius RegaudRan2023 to 2026Enrolled100ConditionsMelanoma, Immune Defect, Tumor Skin
3 · Its place in the literature

Who cites it

996 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,900 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

936 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Frances BalkwillCentre for Cancer and Inflammation, Institute of Cancer, Barts, UK. Frances.balkwill@cancer.org.uk
Cancer Research UK · GB

Funding

Medical Research Council G0501974
6 · The paper itself

Abstract

Tumour necrosis factor (TNF) is a major inflammatory cytokine that was first identified for its ability to induce rapid haemorrhagic necrosis of experimental cancers. When efforts to harness this anti-tumour activity in cancer treatments were underway, a paradoxical tumour-promoting role of TNF became apparent. Now that links between inflammation and cancer are appreciated, is TNF a target or a therapeutic in malignant disease -- or both?

Indexed as

AnimalsClinical Trials as TopicCytotoxicity, ImmunologicDNA DamageEndotoxinsHumansInflammationNeoplasmsReceptors, Tumor Necrosis FactorRecombinant ProteinsTumor Necrosis Factor-alphaEndotoxinsReceptors, Tumor Necrosis FactorRecombinant ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID19343034
OpenAlexW2061294496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.